You are here: Industry Insights > I-Mab

News List

I-Mab Biopharma Receives IND Approval from NMPA to Initiate Clinical Trials for its Anti-GM-CSF Monoclonal Antibody TJM2 in China En-CPhI.CN
November 15, 2019
I-Mab Biopharma, a China and U.S.-based clinical-stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and ...
I-Mab novel antibody gets IND approval in China biospectrumasia
October 08, 2019
TJD5 is currently being investigated in a Phase 1 clinical trial in the U.S. to assess the tolerability and preliminary efficacy both as a single agent and in combination with TECENTRIQ® (atezolizumab), a PD-L1 antibody marketed by Roche in the U.S., and
I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5 En-CPhI.CN
October 08, 2019
I-Mab Biopharma , a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics ...
I-Mab, TRACON initiate Phase 1 Trial of the CD73 antibody TJD5 biospectrumasia
August 04, 2019
TJD5, a novel, differentiated humanized antibody against CD73
I-Mab gets IND approval for TJC4 antibody biospectrumasia
July 15, 2019
TJC4 is a potential global best-in-class CD47 Monoclonal Antibody developed for the treatment of advanced malignant tumors
I-Mab Announces Dosing of First Patient in a Phase I Clinical Trial of TJC4 americanpharmaceuticalreview
June 26, 2019
I-Mab Biopharma announced the first patient has been dosed in a Phase I clinical trial of TJC4. The study is known as TJ011133 (NCT Number: NCT03934814).
WuXi Biologics, I-Mab Biopharma Ink Long-term Strategic Pact contractpharma
April 17, 2019
WuXi to provide CMC development and commercial manufacturing.
I-Mab, Nhwa and CDMO Biodextris Enter Research Collaboration contractpharma
April 15, 2019
Together and along with a Boston-based academic medical center will jointly develop a novel immuno-stimulatory therapy for neurologic disorders...
I-Mab, Jiangsu Nhwa team up with Biodextris, Brigham for treating neuro disorders biospectrumasia
April 10, 2019
I-Mab Biopharma (I-Mab), a clinical stage biotech company based in Shanghai with an exclusive focus on the ^
I-Mab, Jiangsu Nhwa team up with Biodextris, Brigham to treat brain diseases biospectrumasia
April 08, 2019
I-Mab Biopharma (I-Mab), a clinical stage biotech company based in Shanghai with an exclusive focus on the ……

Previous page 1 2 3 4 5 6 Next page